Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: Preliminary report

被引:60
作者
Yokoe T. [1 ]
Lino Y. [1 ]
Morishita Y. [2 ]
机构
[1] Emergency and Critical Care Medicine, Gunma University, School of Medicine, Maebashi, Gunma 371-8511
[2] Second Department of Surgery, Gunma University, School of Medicine.
关键词
Cytokine; IL-6; IL-8; Recurrent breast cancer;
D O I
10.1007/BF02967458
中图分类号
学科分类号
摘要
Background: We reported that IL-6 and IL-8 levels at the beginning of treatment are predictive indicators of response to therapy and prognosis of patients with recurrent breast cancer. The aim of this study was to investigate the trend of IL-6 and IL-8 levels in heavily pretreated patients with recurrent breast cancer. Methods: Cytokine level trends in 12 patients heavily pretreated with anthracyclines were studied. Patients were divided into two groups according to the objective response. There were 5 partial response (PR)/no change (NC), and 7 progressive disease (PD) patients. Blood was taken every four weeks. IL-6 was measured by chemiluminescent enzyme immunoassay. IL-8 was measured by ELISA. Results: The pretreatment level of IL-6 in the PR/NC group (11.0±.2.1 pg/ml) was significantly lower than that (15.3±2.7 pg/ml) in the PD group. However, there was no difference in IL-8 level between the PR/NC group (12.5+±5.5 pg/ml) and the PD group (11.5±1.1 pg/ml). IL-6 levels in the PR/NC group were maintained within normal levels or decreased to within normal levels after treatment, while levels of IL-6 in the PD group gradually increased until the time of patient death. A decrease in IL-8 level after treatment was observed in only one patient in the PR/NC group. Mild increase of IL-8 levels was observed in the PD group. Conclusion: Continuous elevation of IL-6 levels indicates poor prognosis in heavily pretreated patients with recurrent breast cancer. Combination therapy including agents that reduce IL-6 levels will be a new strategy for aggressively treating recurrent breast cancer.
引用
收藏
页码:187 / 190
页数:3
相关论文
共 34 条
[1]  
Kushner I., The acute phase response: An overview, Methods in Enzymology, 163, pp. 373-383, (1988)
[2]  
Hirano T., Yasukawa K., Harada H., Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin, Nature, 324, 6092, pp. 73-76, (1986)
[3]  
Kishimoto T., The biology of interleukin-6, Blood, 74, 1, pp. 1-10, (1989)
[4]  
Detmers P.A., Lo S.K., Olsen-Egbert E., Walz A., Baggiolini M., Cohn Z.A., Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils, Journal of Experimental Medicine, 171, 4, pp. 1155-1162, (1990)
[5]  
Huber A.R., Kunkel S.L., Todd III R.F., Weiss S.J., Regulation of transendothelial neutrophil migration by endogenous interleukin-8, Science, 254, 5028, pp. 99-102, (1991)
[6]  
Strassman G., Fong M., Kenney J.S., Et al., Evidence for the involvement of interleukin 6 in experimental cancer cachexia, J Clin Invest, 89, pp. 1681-1684, (1992)
[7]  
Yasumoto K., Mukaida N., Harada A., Et al., Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice, Cancer Res, 55, pp. 921-927, (1995)
[8]  
Kajimura N., Iseki H., Tanaka R., Et al., Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines, Cancer Chemother Pharmacol, 38, pp. 48-52, (1996)
[9]  
Mobus V.J., Moll R., Gerharz C.D., Kieback D.G., Merk O., Runnebam I.B., Linner S., Dreher L., Grill H.-J., Kreienberg R., Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin, International Journal of Cancer, 77, 3, pp. 415-423, (1998)
[10]  
Kurebayashi J., Otsuki T., Tang C.K., Kurosumi M., Yamamoto S., Tanaka K., Mochizuki M., Nakamura H., Sonoo H., Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6, British Journal of Cancer, 79, 5-6, pp. 707-717, (1999)